Design, Synthesis, Molecular Docking, Antimicrobial and Anticancer Activity of Novel Quinazoline Amino Acid Hybrids | ||
| Egyptian Journal of Chemistry | ||
| Volume 68, Issue 13, December 2025, Pages 867-887 PDF (1.66 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejchem.2025.373139.11550 | ||
| Authors | ||
| Heba A. El-sayed1; Hanan Afifi2; Abdel-Aziz Ebead3; Ibrahim M. Nagy* 4; Abdel-Rahman A. El-Attar1; Adel A.-H. Abdel-Rahman5 | ||
| 1Chemistry Department, Faculty of Science, Menoufia University, Shebin El-Koam, 32511 Egypt | ||
| 2Faculty of Industrial Education, Beni Suef University, Beni Suef, 62512 Egypt | ||
| 3Chemistry Department, Faculty of Science, Arish University, Arish, 45511 Egypt | ||
| 4Medicinal Chemistry Department, Menoufia University, Shebin El-Koam, Egypt | ||
| 5Chemistry Department, Faculty of Science, Menoufia University, Shebin El-Koam, EGYPT. | ||
| Abstract | ||
| A novel series of quinazoline–amino acid hybrids has been synthesized through a multistep synthetic pathway. The synthesized compounds include ester derivatives (3, 4), hydrazide derivatives (5, 6, 13, 17), dipeptides (14–16), and tripeptides (18–20) of quinazoline. Their structures were confirmed via IR, ¹H-NMR, and ¹³C-NMR spectroscopy, along with elemental analysis. The antimicrobial evaluation revealed that all compounds exhibited moderate to strong activity, with compounds 4–6, 15, 16, and 18–20 displaying the most potent antibacterial and antifungal properties. Specifically, compound 6 demonstrated (39 mm, MIC = 8 µM, IC₅₀ = 7 µM) inhibition zone against Bacillus subtilis and (36 mm, MIC = 11 µM, IC₅₀ = 9 µM) inhibition against E. coli , and compound 4 showed strong activity against Escherichia coli with an inhibition of (33 mm, MIC = 13 µM, IC₅₀ = 11 µM). The antifungal activity was also notable, with compound 16 showing (13 mm, MIC = 35 µM, IC₅₀ = 28 µM) inhibition against Candida albicans. Furthermore, molecular docking studies highlighted their strong binding affinities to key microbial targets, with compound 19 exhibiting the top docking score (ΔG = –8.46 kcal/mol), compared to erlotinib (ΔG = –8.51 kcal/mol). In addition, the anticancer potential of the synthesized compounds was assessed in vitro against MCF7 breast cancer cells using the SRB assay. Compound 15 displayed significant cytotoxicity with an IC₅₀ value of 3.40 ± 0.13 µg/mL, demonstrating pharmacological performance comparable to doxorubicin (IC₅₀ = 2.97 ± 0.12 µg/mL). These findings underscore the promising therapeutic applications of quinazoline–amino acid hybrids, warranting further investigation into their biological mechanisms and clinical relevance. | ||
| Keywords | ||
| Keywords: quinazoline; synthesis; hydrazide; peptides; antimicrobial; anticancer | ||
|
Statistics Article View: 154 PDF Download: 13 |
||
